SUPPLEMENT

Q3 2023 — Other Financial Disclosures

Q3 2023PDF · 17 pages1.0 MB
Table 1: Sales by Segment 	1
Table 2: Sales by Geographic Area 	2
Table 3: Sales of Key Products/Franchises 	3 - 7
Table 3a: Supplemental Sales Reconciliation 	8
Table 4: Condensed Consolidated Statement of Earnings - QTD 	9
Table 5: Condensed Consolidated Statement of Earnings - YTD 	10
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 	11
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 	12
Table 8: Non-GAAP Adjusted Net Earnings 	13
Table 9: Non-GAAP IBT by Segment - QTD 	14
Table 10: Non-GAAP IBT by Segment - YTD 	15
Table 11: Non-GAAP P&L Reconciliation 	16
Third Quarter 2023
Other Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
segment of business
Innovative Medicine (1,2)
U.S. 	8,249 	7,438 	10.9 	10.9 	- 	23,090 	21,229 	8.8 	8.8 	-
International 	5,644 	5,776 	(2.3) 	(4.3) 	2.0 	17,947 	18,171 	(1.2) 	0.8 	(2.0)
13,893 	13,214 	5.1 	4.3 	0.8 	41,037 	39,400 	4.2 	5.1 	(0.9)
Innovative Medicine excluding COVID-19 Vaccine (1,2)
U.S. 	8,249 	7,438 	10.9 	10.9 	- 	23,090 	21,109 	9.4 	9.4 	-
International 	5,603 	5,287 	5.9 	4.3 	1.6 	16,874 	16,801 	0.4 	2.7 	(2.3)
13,852 	12,725 	8.9 	8.2 	0.7 	39,964 	37,910 	5.4 	6.4 	(1.0)
MedTech
U.S. 	3,747 	3,356 	11.6 	11.6 	- 	11,345 	9,932 	14.2 	14.2 	-
International 	3,711 	3,426 	8.3 	9.2 	(0.9) 	11,382 	10,719 	6.2 	10.0 	(3.8)
7,458 	6,782 	10.0 	10.4 	(0.4) 	22,727 	20,651 	10.0 	12.0 	(2.0)
U.S. 	11,996 	10,794 	11.1 	11.1 	- 	34,435 	31,161 	10.5 	10.5 	-
International 	9,355 	9,202 	1.6 	0.7 	0.9 	29,329 	28,890 	1.5 	4.2 	(2.7)
Worldwide 	21,351 	19,996 	6.8 	6.4 	0.4 	63,764 	60,051 	6.2 	7.5 	(1.3)
U.S. 	11,996 	10,794 	11.1 	11.1 	- 	34,435 	31,041 	10.9 	10.9 	-
International 	9,314 	8,713 	6.9 	6.3 	0.6 	28,256 	27,520 	2.7 	5.5 	(2.8)
Worldwide excluding COVID-19 Vaccine (1)	
21,310	$ 	19,507 	9.2 % 	9.0 	0.2 	62,691	$ 	58,561 	7.1 % 	8.4 	(1.3)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule
(2) Previously referred to as Pharmaceutical
THIRD QUARTER 	NINE MONTHS
Percent Change

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,996	$ 	10,794 	11.1 % 	11.1 	- 	34,435	$ 	31,161 	10.5 % 	10.5 	-
Europe 	4,727 	4,844 	(2.4) 	(7.8) 	5.4 	15,448 	15,540 	(0.6) 	(1.0) 	0.4
Western Hemisphere excluding U.S. 	1,171 	1,059 	10.5 	12.8 	(2.3) 	3,383 	3,084 	9.7 	15.0 	(5.3)
Asia-Pacific, Africa 	3,457 	3,299 	4.8 	9.4 	(4.6) 	10,498 	10,266 	2.2 	8.7 	(6.5)
International 	9,355 	9,202 	1.6 	0.7 	0.9 	29,329 	28,890 	1.5 	4.2 	(2.7)
Worldwide 	21,351	$ 	19,996 	6.8 % 	6.4 	0.4 	63,764	$ 	60,051 	6.2 % 	7.5 	(1.3)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER 	NINE MONTHS
Percent Change

-- 3 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
INNOVATIVE MEDICINE SEGMENT (2,3,4) 	2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
IMMUNOLOGY
US 	3,193	$ 	2,876 	11.0% 	11.0% 	- 	8,506	$ 	8,230 	3.3% 	3.3% 	-
Intl 	1,656 	1,411 	17.4% 	15.2% 	2.2% 	4,951 	4,587 	7.9% 	10.3% 	-2.4%
WW 	4,849 	4,287 	13.1% 	12.4% 	0.7% 	13,457 	12,817 	5.0% 	5.9% 	-0.9%
REMICADE
US 	296 	350 	-15.4% 	-15.4% 	- 	849 	1,099 	-22.7% 	-22.7% 	-
US Exports (5) 	38 	39 	-2.5% 	-2.5% 	- 	112 	163 	-31.3% 	-31.3% 	-
Intl 	127 	169 	-25.1% 	-24.3% 	-0.8% 	449 	606 	-25.9% 	-23.0% 	-2.9%
WW 	461 	558 	-17.4% 	-17.1% 	-0.3% 	1,410 	1,868 	-24.5% 	-23.6% 	-0.9%
SIMPONI / SIMPONI ARIA
US 	310 	298 	3.9% 	3.9% 	- 	866 	886 	-2.3% 	-2.3% 	-
Intl 	319 	248 	29.1% 	30.2% 	-1.1% 	829 	797 	4.1% 	8.6% 	-4.5%
WW 	629 	545 	15.3% 	15.8% 	-0.5% 	1,695 	1,682 	0.8% 	2.9% 	-2.1%
STELARA
US 	1,912 	1,655 	15.5% 	15.5% 	- 	5,180 	4,766 	8.7% 	8.7% 	-
Intl 	951 	794 	19.9% 	16.2% 	3.7% 	2,925 	2,571 	13.8% 	15.5% 	-1.7%
WW 	2,864 	2,449 	16.9% 	15.8% 	1.1% 	8,105 	7,336 	10.5% 	11.1% 	-0.6%
TREMFYA
US 	634 	530 	19.6% 	19.6% 	- 	1,490 	1,303 	14.4% 	14.4% 	-
Intl 	258 	200 	29.0% 	26.3% 	2.7% 	747 	613 	21.9% 	24.0% 	-2.1%
WW 	891 	729 	22.2% 	21.5% 	0.7% 	2,237 	1,916 	16.8% 	17.4% 	-0.6%
OTHER IMMUNOLOGY
US 	2 	5 	-47.1% 	-47.1% 	- 	9 	14 	-36.1% 	-36.1% 	-
Intl 	0 	0 	- 	- 	- 	0 	0 	- 	- 	-
WW 	2 	5 	-47.1% 	-47.1% 	- 	9 	14 	-36.1% 	-36.1% 	-
INFECTIOUS DISEASES
US 	360 	390 	-7.8% 	-7.8% 	- 	1,147 	1,266 	-9.4% 	-9.4% 	-
Intl 	500 	905 	-44.8% 	-50.7% 	5.9% 	2,420 	2,642 	-8.4% 	-9.3% 	0.9%
WW 	859 	1,295 	-33.6% 	-37.8% 	4.2% 	3,566 	3,908 	-8.7% 	-9.3% 	0.6%
COVID-19 VACCINE
US 	0 	0 	- 	- 	- 	0 	120 	* 	* 	-
Intl 	41 	489 	-91.5% 	-97.8% 	6.3% 	1,073 	1,370 	-21.6% 	-23.0% 	1.4%
WW 	41 	489 	-91.5% 	-97.8% 	6.3% 	1,073 	1,490 	-27.9% 	-29.2% 	1.3%
EDURANT / rilpivirine
US 	9 	9 	10.2% 	10.2% 	- 	26 	27 	-0.5% 	-0.5% 	-
Intl 	287 	237 	21.4% 	13.4% 	8.0% 	816 	691 	18.2% 	16.4% 	1.8%
WW 	297 	245 	21.0% 	13.3% 	7.7% 	843 	718 	17.5% 	15.8% 	1.7%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	345 	372 	-7.3% 	-7.3% 	- 	1,105 	1,096 	0.9% 	0.9% 	-
Intl 	102 	112 	-9.5% 	-15.0% 	5.5% 	310 	354 	-12.5% 	-13.0% 	0.5%
WW 	447 	485 	-7.8% 	-9.0% 	1.2% 	1,415 	1,450 	-2.4% 	-2.5% 	0.1%
OTHER INFECTIOUS DISEASES
US 	5 	10 	-42.7% 	-42.7% 	- 	15 	24 	-35.5% 	-35.5% 	-
Intl 	69 	68 	2.0% 	5.5% 	-3.5% 	220 	228 	-3.4% 	0.8% 	-4.2%
WW 	74 	77 	-3.6% 	-0.5% 	-3.1% 	235 	251 	-6.4% 	-2.6% 	-3.8%
NINE MONTHS
% Change 	% Change

-- 4 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
NEUROSCIENCE
US 	1,036 	919 	12.7% 	12.7% 	- 	3,043 	2,658 	14.5% 	14.5% 	-
Intl 	706 	763 	-7.4% 	-5.1% 	-2.3% 	2,296 	2,498 	-8.1% 	-4.2% 	-3.9%
WW 	1,742 	1,681 	3.6% 	4.6% 	-1.0% 	5,339 	5,156 	3.5% 	5.4% 	-1.9%
CONCERTA / Methylphenidate
US 	57 	41 	38.1% 	38.1% 	- 	191 	114 	67.4% 	67.4% 	-
Intl 	133 	117 	13.6% 	15.5% 	-1.9% 	412 	362 	13.8% 	19.0% 	-5.2%
WW 	189 	158 	20.0% 	21.4% 	-1.4% 	603 	476 	26.7% 	30.7% 	-4.0%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	730 	684 	6.8% 	6.8% 	- 	2,164 	2,036 	6.3% 	6.3% 	-
Intl 	299 	348 	-14.0% 	-14.4% 	0.4% 	940 	1,097 	-14.3% 	-11.9% 	-2.4%
WW 	1,029 	1,031 	-0.2% 	-0.3% 	0.1% 	3,104 	3,132 	-0.9% 	-0.1% 	-0.8%
SPRAVATO
US 	154 	88 	75.1% 	75.1% 	- 	409 	223 	83.1% 	83.1% 	-
Intl 	29 	12 	* 	* 	* 	74 	32 	* 	* 	*
WW 	183 	100 	82.1% 	81.0% 	1.1% 	483 	255 	88.8% 	88.7% 	0.1%
OTHER NEUROSCIENCE
US 	94 	106 	-11.3% 	-11.3% 	- 	278 	285 	-2.3% 	-2.3% 	-
Intl 	245 	286 	-13.9% 	-7.8% 	-6.1% 	870 	1,007 	-13.5% 	-8.5% 	-5.0%
WW 	340 	393 	-13.2% 	-8.7% 	-4.5% 	1,149 	1,293 	-11.0% 	-7.1% 	-3.9%
ONCOLOGY
US 	2,219 	1,812 	22.5% 	22.5% 	- 	6,177 	5,073 	21.8% 	21.8% 	-
Intl 	2,313 	2,252 	2.7% 	0.7% 	2.0% 	6,865 	6,983 	-1.7% 	0.3% 	-2.0%
WW 	4,533 	4,064 	11.5% 	10.4% 	1.1% 	13,043 	12,056 	8.2% 	9.3% 	-1.1%
CARVYKTI
US 	140 	55 	* 	* 	- 	324 	79 	* 	* 	-
Intl 	12 	- 	* 	* 	- 	17 	- 	* 	* 	-
WW 	152 	55 	* 	* 	- 	341 	79 	* 	* 	-
DARZALEX
US 	1,369 	1,097 	24.8% 	24.8% 	- 	3,882 	3,071 	26.4% 	26.4% 	-
Intl 	1,130 	955 	18.3% 	16.0% 	2.3% 	3,312 	2,823 	17.3% 	19.7% 	-2.4%
WW 	2,499 	2,052 	21.8% 	20.7% 	1.1% 	7,194 	5,894 	22.1% 	23.2% 	-1.1%
ERLEADA
US 	288 	254 	12.9% 	12.9% 	- 	778 	693 	12.2% 	12.2% 	-
Intl 	342 	235 	45.8% 	42.3% 	3.5% 	961 	647 	48.7% 	51.0% 	-2.3%
WW 	631 	490 	28.7% 	27.0% 	1.7% 	1,740 	1,340 	29.8% 	30.9% 	-1.1%
IMBRUVICA
US 	264 	353 	-25.2% 	-25.2% 	- 	796 	1,072 	-25.8% 	-25.8% 	-
Intl 	545 	559 	-2.5% 	-4.6% 	2.1% 	1,681 	1,847 	-9.0% 	-7.6% 	-1.4%
WW 	808 	911 	-11.3% 	-12.6% 	1.3% 	2,476 	2,918 	-15.2% 	-14.2% 	-1.0%
ZYTIGA / abiraterone acetate
US 	16 	16 	-2.8% 	-2.8% 	- 	41 	54 	-24.9% 	-24.9% 	-
Intl 	199 	440 	-54.9% 	-55.1% 	0.2% 	646 	1,446 	-55.3% 	-53.6% 	-1.7%
WW 	214 	456 	-53.0% 	-53.2% 	0.2% 	686 	1,500 	-54.2% 	-52.6% 	-1.6%
OTHER ONCOLOGY
US 	143 	37 	* 	* 	- 	357 	104 	* 	* 	-
Intl 	86 	64 	34.5% 	30.4% 	4.1% 	248 	220 	12.5% 	13.8% 	-1.3%
WW 	229 	100 	* 	* 	* 	605 	324 	86.5% 	87.4% 	-0.9%
NINE MONTHS
% Change 	% Change

-- 5 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 	680 	604 	12.6% 	12.6% 	- 	1,964 	1,736 	13.1% 	13.1% 	-
Intl 	274 	247 	10.5% 	11.7% 	-1.2% 	835 	810 	3.0% 	7.4% 	-4.4%
WW 	954 	852 	12.0% 	12.4% 	-0.4% 	2,798 	2,547 	9.9% 	11.3% 	-1.4%
OPSUMIT
US 	323 	289 	12.2% 	12.2% 	- 	924 	827 	11.8% 	11.8% 	-
Intl 	166 	152 	9.3% 	8.6% 	0.7% 	512 	495 	3.5% 	6.8% 	-3.3%
WW 	490 	441 	11.2% 	10.9% 	0.3% 	1,437 	1,322 	8.7% 	9.9% 	-1.2%
UPTRAVI
US 	336 	283 	18.9% 	18.9% 	- 	978 	824 	18.7% 	18.7% 	-
Intl 	66 	50 	30.9% 	33.8% 	-2.9% 	185 	162 	14.1% 	18.6% 	-4.5%
WW 	402 	333 	20.7% 	21.1% 	-0.4% 	1,163 	986 	18.0% 	18.7% 	-0.7%
OTHER PULMONARY HYPERTENSION
US 	20 	33 	-37.1% 	-37.1% 	- 	61 	86 	-28.4% 	-28.4% 	-
Intl 	42 	46 	-7.5% 	-2.1% 	-5.4% 	137 	154 	-10.5% 	-2.6% 	-7.9%
WW 	63 	78 	-19.8% 	-16.6% 	-3.2% 	199 	239 	-16.9% 	-11.8% 	-5.1%
CARDIOVASCULAR / METABOLISM / OTHER
US 	763 	837 	-8.8% 	-8.8% 	- 	2,254 	2,266 	-0.5% 	-0.5% 	-
Intl 	194 	198 	-2.1% 	-4.7% 	2.6% 	580 	651 	-10.8% 	-9.8% 	-1.0%
WW 	957 	1,034 	-7.5% 	-8.0% 	0.5% 	2,834 	2,916 	-2.8% 	-2.6% 	-0.2%
XARELTO
US 	625 	689 	-9.4% 	-9.4% 	- 	1,840 	1,806 	1.9% 	1.9% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	625 	689 	-9.4% 	-9.4% 	- 	1,840 	1,806 	1.9% 	1.9% 	-
OTHER
US 	139 	147 	-6.1% 	-6.1% 	- 	414 	459 	-9.9% 	-9.9% 	-
Intl 	194 	198 	-2.1% 	-4.7% 	2.6% 	580 	651 	-10.8% 	-9.8% 	-1.0%
WW 	332 	345 	-3.8% 	-5.3% 	1.5% 	994 	1,110 	-10.5% 	-9.8% 	-0.7%
TOTAL INNOVATIVE MEDICINE
US 	8,249 	7,438 	10.9% 	10.9% 	- 	23,090 	21,229 	8.8% 	8.8% 	-
Intl 	5,644 	5,776 	-2.3% 	-4.3% 	2.0% 	17,947 	18,171 	-1.2% 	0.8% 	-2.0%
WW 	13,893	$ 	13,214 	5.1% 	4.3% 	0.8% 	41,037	$ 	39,400 	4.2% 	5.1% 	-0.9%
See footnotes at end of schedule
NINE MONTHS
% Change 	% Change

-- 6 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
MEDTECH SEGMENT (2,3) 	2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	891	$ 	547 	63.0% 	63.0% 	- 	2,662	$ 	1,566 	70.0% 	70.0% 	-
Intl 	667 	513 	29.9% 	32.2% 	-2.3% 	2,019 	1,636 	23.4% 	28.6% 	-5.2%
WW 	1,558 	1,060 	47.0% 	48.1% 	-1.1% 	4,681 	3,202 	46.2% 	48.9% 	-2.7%
ELECTROPHYSIOLOGY
US 	611 	520 	17.6% 	17.6% 	- 	1,791 	1,489 	20.3% 	20.3% 	-
Intl 	549 	453 	21.2% 	23.4% 	-2.2% 	1,658 	1,454 	14.0% 	19.2% 	-5.2%
WW 	1,161 	973 	19.3% 	20.3% 	-1.0% 	3,449 	2,943 	17.2% 	19.8% 	-2.6%
ABIOMED
US 	254 	- 	* 	* 	- 	790 	- 	* 	* 	-
Intl 	57 	- 	* 	* 	- 	176 	- 	* 	* 	-
WW 	311 	- 	* 	* 	- 	966 	- 	* 	* 	-
OTHER INTERVENTIONAL SOLUTIONS
US 	26 	27 	-3.2% 	-3.2% 	- 	81 	77 	5.9% 	5.9% 	-
Intl 	61 	60 	1.0% 	3.7% 	-2.7% 	186 	181 	2.2% 	7.2% 	-5.0%
WW 	87 	87 	-0.3% 	1.6% 	-1.9% 	267 	258 	3.3% 	6.8% 	-3.5%
ORTHOPAEDICS
US 	1,349 	1,309 	3.1% 	3.1% 	- 	4,100 	3,936 	4.2% 	4.2% 	-
Intl 	815 	785 	3.9% 	1.7% 	2.2% 	2,574 	2,504 	2.8% 	4.9% 	-2.1%
WW 	2,164 	2,095 	3.4% 	2.6% 	0.8% 	6,674 	6,440 	3.6% 	4.5% 	-0.9%
HIPS
US 	239 	228 	4.9% 	4.9% 	- 	730 	693 	5.4% 	5.4% 	-
Intl 	136 	124 	9.3% 	7.3% 	2.0% 	432 	437 	-1.0% 	1.1% 	-2.1%
WW 	375 	352 	6.5% 	5.8% 	0.7% 	1,162 	1,129 	2.9% 	3.8% 	-0.9%
KNEES
US 	207 	203 	2.3% 	2.3% 	- 	654 	620 	5.6% 	5.6% 	-
Intl 	131 	115 	14.6% 	11.7% 	2.9% 	415 	386 	7.7% 	9.7% 	-2.0%
WW 	338 	317 	6.7% 	5.7% 	1.0% 	1,069 	1,005 	6.4% 	7.2% 	-0.8%
TRAUMA
US 	488 	473 	3.2% 	3.2% 	- 	1,462 	1,412 	3.5% 	3.5% 	-
Intl 	253 	244 	4.2% 	0.8% 	3.4% 	775 	749 	3.5% 	5.0% 	-1.5%
WW 	742 	717 	3.5% 	2.4% 	1.1% 	2,238 	2,161 	3.5% 	4.0% 	-0.5%
SPINE, SPORTS & OTHER
US 	415 	406 	2.3% 	2.3% 	- 	1,254 	1,211 	3.5% 	3.5% 	-
Intl 	295 	303 	-2.6% 	-3.6% 	1.0% 	952 	933 	2.0% 	4.7% 	-2.7%
WW 	710 	708 	0.2% 	-0.2% 	0.4% 	2,205 	2,144 	2.8% 	4.0% 	-1.2%
NINE MONTHS
% Change 	% Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
SURGERY
US 	994 	984 	1.1% 	1.1% 	- 	2,984 	2,897 	3.0% 	3.0% 	-
Intl 	1,483 	1,439 	3.1% 	4.6% 	-1.5% 	4,522 	4,410 	2.6% 	6.7% 	-4.1%
WW 	2,479 	2,422 	2.3% 	3.2% 	-0.9% 	7,507 	7,306 	2.7% 	5.3% 	-2.6%
ADVANCED
US 	455 	457 	-0.4% 	-0.4% 	- 	1,365 	1,328 	2.8% 	2.8% 	-
Intl 	709 	701 	1.0% 	2.7% 	-1.7% 	2,139 	2,132 	0.3% 	4.5% 	-4.2%
WW 	1,164 	1,158 	0.5% 	1.5% 	-1.0% 	3,504 	3,460 	1.3% 	3.8% 	-2.5%
GENERAL
US 	540 	527 	2.4% 	2.4% 	- 	1,619 	1,569 	3.2% 	3.2% 	-
Intl 	775 	737 	5.1% 	6.5% 	-1.4% 	2,383 	2,277 	4.7% 	8.8% 	-4.1%
WW 	1,314 	1,264 	4.0% 	4.8% 	-0.8% 	4,002 	3,846 	4.1% 	6.5% 	-2.4%
VISION
US 	512 	517 	-1.0% 	-1.0% 	- 	1,599 	1,534 	4.2% 	4.2% 	-
Intl 	744 	689 	8.1% 	10.1% 	-2.0% 	2,265 	2,170 	4.4% 	8.3% 	-3.9%
WW 	1,256 	1,206 	4.2% 	5.4% 	-1.2% 	3,864 	3,704 	4.3% 	6.6% 	-2.3%
CONTACT LENSES / OTHER
US 	399 	405 	-1.2% 	-1.2% 	- 	1,252 	1,179 	6.2% 	6.2% 	-
Intl 	529 	503 	4.9% 	8.2% 	-3.3% 	1,568 	1,533 	2.3% 	7.0% 	-4.7%
WW 	928 	908 	2.2% 	4.0% 	-1.8% 	2,820 	2,712 	4.0% 	6.6% 	-2.6%
SURGICAL
US 	112 	112 	-0.1% 	-0.1% 	- 	346 	355 	-2.5% 	-2.5% 	-
Intl 	216 	186 	16.6% 	15.4% 	1.2% 	698 	637 	9.6% 	11.7% 	-2.1%
WW 	328 	298 	10.3% 	9.5% 	0.8% 	1,044 	992 	5.3% 	6.6% 	-1.3%
TOTAL MEDTECH
US 	3,747 	3,356 	11.6% 	11.6% 	- 	11,345 	9,932 	14.2% 	14.2% 	-
Intl 	3,711 	3,426 	8.3% 	9.2% 	-0.9% 	11,382 	10,719 	6.2% 	10.0% 	-3.8%
WW 	7,458	$ 	6,782 	10.0% 	10.4% 	-0.4% 	22,727	$ 	20,651 	10.0% 	12.0% 	-2.0%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Previously referred to as Pharmaceutical
(5) Reported as U.S. sales
NINE MONTHS
% Change 	% Change
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely

-- 8 of 17 --

2023 	2022 	Total 	Operations Currency 	2023 	2022 	Total 	Operations Currency
Innovative Medicine
U.S. 	8,249	$ 	7,438 	10.9 % 	10.9 	- 	23,090	$ 	21,229 	8.8 % 	8.8 	-
International 	5,644 	5,776 	(2.3) 	(4.3) 	2.0 	17,947 	18,171 	(1.2) 	0.8 	(2.0)
Worldwide 	13,893 	13,214 	5.1 	4.3 	0.8 	41,037 	39,400 	4.2 	5.1 	(0.9)
COVID-19 Vaccine
U.S. 	- 	- 	- 	- 	- 	- 	120 	* 	* 	-
International 	41 	489 	(91.5) 	(97.8) 	6.3 	1,073 	1,370 	(21.6) 	(23.0) 	1.4
Worldwide 	41 	489 	(91.5) 	(97.8) 	6.3 	1,073 	1,490 	(27.9) 	(29.2) 	1.3
Innovative Medicine excluding COVID-19 Vaccine
U.S. 	8,249 	7,438 	10.9 	10.9 	- 	23,090 	21,109 	9.4 	9.4 	-
International 	5,603 	5,287 	5.9 	4.3 	1.6 	16,874 	16,801 	0.4 	2.7 	(2.3)
Worldwide 	13,852 	12,725 	8.9 	8.2 	0.7 	39,964 	37,910 	5.4 	6.4 	(1.0)
Worldwide
U.S. 	11,996 	10,794 	11.1 	11.1 	- 	34,435 	31,161 	10.5 	10.5 	-
International 	9,355 	9,202 	1.6 	0.7 	0.9 	29,329 	28,890 	1.5 	4.2 	(2.7)
Worldwide 	21,351 	19,996 	6.8 	6.4 	0.4 	63,764 	60,051 	6.2 	7.5 	(1.3)
COVID-19 Vaccine
U.S. 	- 	- 	- 	- 	- 	- 	120 	* 	* 	-
International 	41 	489 	(91.5) 	(97.8) 	6.3 	1,073 	1,370 	(21.6) 	(23.0) 	1.4
Worldwide 	41 	489 	(91.5) 	(97.8) 	6.3 	1,073 	1,490 	(27.9) 	(29.2) 	1.3
Worldwide
U.S. 	11,996 	10,794 	11.1 	11.1 	- 	34,435 	31,041 	10.9 	10.9 	-
International 	9,314 	8,713 	6.9 	6.3 	0.6 	28,256 	27,520 	2.7 	5.5 	(2.8)
Worldwide excluding COVID-19 Vaccine 	21,310	$ 	19,507 	9.2 % 	9.0 	0.2 	62,691	$ 	58,561 	7.1 % 	8.4 	(1.3)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
THIRD QUARTER 	NINE MONTHS
Percent Change 	Percent Change

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	21,351	$ 	100.0 	19,996	$ 	100.0 	6.8
Cost of products sold 	6,606 	30.9 	6,172 	30.9 	7.0
Gross Profit 	14,745 	69.1 	13,824 	69.1 	6.7
Selling, marketing and administrative expenses 	5,400 	25.3 	4,975 	24.9 	8.5
Research and development expense 	3,447 	16.2 	3,485 	17.4 	(1.1)
In-process research and development impairments 	206 	1.0 	- 	-
Interest (income) expense, net 	(182) 	(0.8) 	(99) 	(0.5)
Other (income) expense, net 	499 	2.3 	226 	1.1
Restructuring 	158 	0.7 	65 	0.3
Earnings before provision for taxes on income 	5,217 	24.4 	5,172 	25.9 	0.9
Provision for taxes on income 	908 	4.2 	862 	4.3 	5.3
Net earnings from Continuing Operations 	4,309	$ 	20.2 	4,310	$ 	21.6 	0.0
Net earnings from Discontinued Operations, net of tax 	21,719 	148
Net earnings 	26,028	$ 	4,458	$
Net earnings per share (Diluted) from Continuing Operations 	1.69	$ 	1.62	$ 	4.3
Net earnings per share (Diluted) from Discontinued Operations 	8.52	$ 	0.06	$
Average shares outstanding (Diluted) 	2,549.7 	2,661.3
Effective tax rate from Continuing Operations 	17.4 % 	16.7 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 	8,033	$ 	37.6 	7,060	$ 	35.3 	13.8
Net earnings from Continuing Operations 	6,777	$ 	31.7 	5,938	$ 	29.7 	14.1
Net earnings per share (Diluted) from Continuing Operations 	2.66	$ 	2.23	$ 	19.3
Effective tax rate from Continuing Operations 	15.6 % 	15.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2023 	2022

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	63,764	$ 	100.0 	60,051	$ 	100.0 	6.2
Cost of products sold 	19,755 	31.0 	18,512 	30.8 	6.7
Gross Profit 	44,009 	69.0 	41,539 	69.2 	5.9
Selling, marketing and administrative expenses 	15,702 	24.6 	14,907 	24.8 	5.3
Research and development expense 	10,605 	16.6 	10,425 	17.4 	1.7
In-process research and development impairments 	255 	0.4 	610 	1.0
Interest (income) expense, net 	(277) 	(0.4) 	(137) 	(0.2)
Other (income) expense, net 	7,055 	11.1 	15 	0.0
Restructuring 	433 	0.6 	200 	0.4
Earnings before provision for taxes on income 	10,236 	16.1 	15,519 	25.8 	(34.0)
Provision for taxes on income 	1,042 	1.7 	2,376 	3.9 	(56.1)
Net earnings from Continuing Operations 	9,194	$ 	14.4 	13,143	$ 	21.9 	(30.0)
Net earnings from Discontinued Operations, net of tax 	21,910 	1,278
Net earnings 	31,104	$ 	14,421	$
Net earnings per share (Diluted) from Continuing Operations 	3.53	$ 	4.93	$ 	(28.4)
Net earnings per share (Diluted) from Discontinued Operations 	8.42	$ 	0.48	$
Average shares outstanding (Diluted) 	2,603.4 	2,667.5
Effective tax rate from Continuing Operations 	10.2 % 	15.3 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 	23,574	$ 	37.0 	21,491	$ 	35.8 	9.7
Net earnings from Continuing Operations 	19,847	$ 	31.1 	18,364	$ 	30.6 	8.1
Net earnings per share (Diluted) from Continuing Operations 	7.62	$ 	6.89	$ 	10.6
Effective tax rate from Continuing Operations 	15.8 % 	14.6 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2023 	2022

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	5.1% 	10.0% 	6.8%
U.S. 	10.9% 	11.6% 	11.1%
International 	(2.3)% 	8.3% 	1.6%
WW Currency 	0.8 	(0.4) 	0.4
U.S. 	- 	- 	-
International 	2.0 	(0.9) 	0.9
WW Operational 	4.3% 	10.4% 	6.4%
U.S. 	10.9% 	11.6% 	11.1%
International 	(4.3)% 	9.2% 	0.7%
Abiomed 	(4.6) 	(1.6)
U.S. 	(7.6) 	(2.3)
International 	(1.7) 	(0.6)
All Other Acquisitions and Divestitures 	0.1 	0.2 	0.1
U.S. 	0.0 	0.3 	0.1
International 	0.2 	0.1 	0.2
WW Adjusted Operational 	4.4% 	6.0% 	4.9%
U.S. 	10.9% 	4.3% 	8.9%
International 	(4.1)% 	7.6% 	0.3%
Adjusted Operational Sales Growth
THIRD QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	4.2% 	10.0% 	6.2%
U.S. 	8.8% 	14.2% 	10.5%
International 	(1.2)% 	6.2% 	1.5%
WW Currency 	(0.9) 	(2.0) 	(1.3)
U.S. 	- 	- 	-
International 	(2.0) 	(3.8) 	(2.7)
WW Operational 	5.1% 	12.0% 	7.5%
U.S. 	8.8% 	14.2% 	10.5%
International 	0.8% 	10.0% 	4.2%
Abiomed 	(4.7) 	(1.6)
U.S. 	(7.9) 	(2.5)
International 	(1.6) 	(0.6)
All Other Acquisitions and Divestitures 	0.1 	0.1 	0.1
U.S. 	0.0 	0.1 	0.0
International 	0.2 	0.0 	0.1
WW Adjusted Operational 	5.2% 	7.4% 	6.0%
U.S. 	8.8% 	6.4% 	8.0%
International 	1.0% 	8.4% 	3.7%
Adjusted Operational Sales Growth
NINE MONTHS 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2023 	2022 	2023 	2022
Net Earnings from Continuing Operations, after tax- as reported 	$4,309 	$4,310 	$9,194 	$13,143
Pre-tax Adjustments
Litigation related 	(51) 	219 	6,986 	604
Intangible Asset Amortization expense 	1,132 	958 	3,384 	2,967
COVID-19 Vaccine related costs 1 	44 	377 	653 	653
Restructuring related 2 	384 	92 	659 	253
Medical Device Regulation 3 	74 	78 	223 	208
Acquisition, integration and divestiture related 	22 	- 	102 	-
(Gains)/losses on securities 	1,005 	164 	1,076 	684
IPR&D impairments 	206 	- 	255 	610
Other 	- 	- 	- 	(7)
Tax Adjustments
Tax impact on special item adjustments 4 	(482) 	(312) 	(2,769) 	(900)
Tax legislation and other tax related 	134 	52 	84 	149
Adjusted Net Earnings from Continuing Operations, after tax 	$6,777 	$5,938 	$19,847 	$18,364
Average shares outstanding (Diluted) 	2,549.7 	2,661.3 	2,603.4 	2,667.5
Adjusted net earnings per share from Continuing Operations (Diluted) 	$2.66 	$2.23 	$7.62 	$6.89
Operational adjusted net earnings per share from Continuing Operations (Diluted) 	$2.54 	$7.60
Notes:
1
2
3
4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in
arriving at adjusted earnings.
Third Quarter 	Nine Months Ended
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required
clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus
on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D
program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program,
hepatitis and HIV development. The restructuring expenses of $149 million in the quarter ($424 million Q3 YTD) include the termination of partnered and
non-partnered program costs and asset impairments.
In the third quarter of 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline
operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense in the quarter of $235 million
primarily includes inventory and instrument reserves related to the market and product exits.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a
replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were
required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change
and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech
operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed
during 2024.

-- 14 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment From Continuing Operations $ 	4,794 	4,186 	1,185 	1,090 	(762) 	(104) 	5,217 	5,172
% to Sales 	34.5% 	31.7% 	15.9% 	16.1% 	-3.6% 	-0.5% 	24.4% 	25.9%
Intangible asset amortization expense 	749 	698 	383 	260 	- 	- 	1,132 	958
In-process research and development impairments 	206 	- 	- 	- 	- 	- 	206 	-
Litigation related 	(32) 	7 	(19) 	212 	- 	- 	(51) 	219
Loss/(gain) on securities 	398 	177 	(38) 	(13) 	645 	- 	1,005 	164
Restructuring related 	149 	23 	235 	69 	- 	- 	384 	92
Acquisition, integration and divestiture related 	- 	- 	22 	- 	- 	- 	22 	-
Medical Device Regulation 	- 	- 	74 	78 	- 	- 	74 	78
COVID-19 Vaccine related costs 	44 	377 	- 	- 	- 	- 	44 	377
Adjusted Income Before Tax by Segment From Continuing Operations 	$ 	6,308 	5,468 	1,842 	1,696 	(117) 	(104) 	8,033 	7,060
% to Sales 	45.4% 	41.4% 	24.7% 	25.0% 	-0.5% 	-0.5% 	37.6% 	35.3%
*Estimated as of 10/17/2023
Q3 QTD - Income Before Tax by Segment*
Dollars in Millions
Innovative Medicine 	MedTech 	Unallocated 	Worldwide Total

-- 15 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment From Continuing Operations $ 	14,008 	12,424 	4,265 	3,641 	(8,037) 	(546) 	10,236 	15,519
% to Sales 	34.1% 	31.5% 	18.8% 	17.6% 	-12.6% 	-0.9% 	16.1% 	25.8%
Intangible asset amortization expense 	2,236 	2,194 	1,148 	773 	- 	- 	3,384 	2,967
In-process research and development impairments 	206 	610 	49 	- 	- 	- 	255 	610
Litigation related 	(125) 	28 	41 	476 	7,070 	100 	6,986 	604
Loss/(gain) on securities 	474 	673 	(43) 	11 	645 	- 	1,076 	684
Restructuring related 	424 	32 	235 	221 	- 	- 	659 	253
Acquisition, integration and divestiture related 	- 	- 	102 	- 	- 	- 	102 	-
Medical Device Regulation 	- 	- 	223 	208 	- 	- 	223 	208
COVID-19 Vaccine related costs 	653 	653 	- 	- 	- 	- 	653 	653
Other 	- 	- 	- 	- 	- 	(7) 	- 	(7)
Adjusted Income Before Tax by Segment From Continuing Operations 	$ 	17,876 	16,614 	6,020 	5,330 	(322) 	(453) 	23,574 	21,491
% to Sales 	43.6% 	42.2% 	26.5% 	25.8% 	-0.5% 	-0.8% 	37.0% 	35.8%
*Estimated as of 10/17/2023
Q3 YTD - Income Before Tax by Segment*
Dollars in Millions
Innovative Medicine 	MedTech 	Unallocated 	Worldwide Total

-- 16 of 17 --

Third Quarter
Oct. 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Third Quarter
Oct. 1, 2023
Non-GAAP
Cost of products sold 	6,606	$ 	(1,132) 	(226) 	(34) 	(9) 	- 	- 	- 	5,205
Selling, marketing and admin expenses 	5,400 	(6) 	5,394
Research and development expense 	3,447 	- 	(33) 	(36) 	3,378
Other (Income) / Expense 	499 	- 	51 	- 	(22) 	(1,005) 	- 	- 	- 	(477)
In-process research and development impairments 	206 	(206) 	-
Interest (Income)/Expense 	(182) 	(182)
Restructuring 	158 	(158) 	-
Provision for taxes on income 	908 	178 	(12) 	46 	72 	5 	167 	14 	12 	27 	(161) 	- 	1,256
Net Earnings from Continuing Operations 	4,309 	954 	(39) 	160 	312 	17 	838 	59 	33 	(27) 	161 	- 	6,777
Third Quarter
Oct. 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Third Quarter
Oct. 2, 2022
Non-GAAP
Cost of products sold 	6,172	$ 	(958) 	(9) 	(29) 	(102) 	- 	- 	- 	5,074
Selling, marketing and admin expenses 	4,975 	(7) 	4,968
Research and development expense 	3,485 	- 	(42) 	(80) 	3,363
Other (Income) / Expense 	226 	- 	(219) 	(18) 	- 	(164) 	(195) 	- 	- 	(370)
In-process research and development impairments 	- 	- 	-
Restructuring 	65 	(65) 	-
Provision for taxes on income 	862 	146 	(7) 	- 	19 	- 	43 	15 	96 	36 	(88) 	- 	1,122
Net Earnings from Continuing Operations 	4,310 	812 	226 	- 	73 	- 	121 	63 	281 	(36) 	88 	- 	5,938
Nine Months
Oct. 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Nine Months
Oct. 1, 2023
Non-GAAP
Cost of products sold 	19,755	$ 	(3,380) 	(226) 	(91) 	(177) 	15,881
Selling, marketing and admin expenses 	15,702 	(21) 	15,681
Research and development expense 	10,605 	(16) 	(111) 	(98) 	10,380
Other (Income) / Expense 	7,055 	(4) 	(6,986) 	- 	(86) 	(1,076) 	(378) 	- 	- 	(1,475)
In-process research and development impairments 	255 	(255) 	- 	- 	- 	-
Interest (Income)/Expense 	(277) 	(277)
Restructuring 	433 	(433) 	-
Provision for taxes on income 	1,042 	532 	1,639 	57 	141 	22 	182 	41 	155 	33 	(117) 	- 	3,727
Net Earnings from Continuing Operations 	9,194 	2,852 	5,347 	198 	518 	80 	894 	182 	498 	(33) 	117 	- 	19,847
Nine Months
Oct. 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Nine Months
Oct. 2, 2022
Non-GAAP
Cost of products sold 	18,512	$ 	(2,967) 	(37) 	(76) 	(296) 	15,136
Selling, marketing and admin expenses 	14,907 	(19) 	14,888
Research and development expense 	10,425 	- 	(113) 	(190) 	10,122
Other (Income) / Expense 	15 	- 	(604) 	(16) 	- 	(684) 	(167) 	- 	7 	(1,449)
In-process research and development impairments 	610 	(610) 	-
Restructuring 	200 	(200) 	-
Provision for taxes on income 	2,376 	442 	(89) 	138 	47 	- 	164 	39 	161 	(62) 	(87) 	(2) 	3,127
Net Earnings from Continuing Operations 	13,143 	2,525 	693 	472 	206 	- 	520 	169 	492 	62 	87 	(5) 	18,364
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation
and other tax
related
Year to Date
Consumer Health
separation tax
related costs
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
Consumer Health
separation tax
related costs
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation
and other tax
related

-- 17 of 17 --